WuXi Biologics recognized by BioPharma APAC for leading sustainable biopharma practices in 2026

BioPharma APAC has named WuXi Biologics in its Top 26 - Companies Leading Sustainable Biopharma Practices in 2026, recognizing the company in Shanghai, China, for its leadership in sustainable biopharmaceutical development and manufacturing.

The 2026 list highlights how global pharmaceutical companies, biotechnology firms and CRDMOs across Europe, North America and Asia Pacific are advancing Science Based Targets initiative (SBTi) commitments, value-chain decarbonization, green manufacturing and sustainable operations.

WuXi Biologics was featured alongside global pharmaceutical leaders such as MSD (Merck & Co.), Eli Lilly, Johnson & Johnson, AstraZeneca, Takeda, GSK and Bayer for its outstanding sustainability practices and empowering contributions through its Green CRDMO solution.

Sustainability as a driver of biopharma innovation and competitiveness

Sustainability is evolving from a corporate social responsibility requirement into a key driver of industry advancement and corporate competitiveness. In the biopharmaceutical industry, climate change, resource efficiency and supply-chain governance have become core areas of focus. Companies are increasingly seeking ways to pursue innovation and business growth while advancing a greener, lower-carbon and more sustainable development model.

Green CRDMO: Sustainability in action at WuXi Biologics

WuXi Biologics has positioned its Green CRDMO solution as sustainability in action. This integrated capability is designed to be practical, measurable and empowering, connecting sustainability progress with productivity, operational resilience and long-term competitiveness to create tangible and sustainable value for global clients.

Across the global healthcare and biopharmaceutical value chain, sustainability is becoming a strategic priority for creating business value. Companies are expected to set science-based climate targets and net-zero commitments, reduce Scope 3 value-chain carbon emissions, quantify product carbon footprints, respond to global green procurement requirements and disclose environmental performance with greater transparency.

The Green CRDMO solution is not an add-on to traditional services, but a bridge that translates governance practices into business value. It helps clients enhance corporate governance, reduce operating costs, capture green-financing opportunities, establish product-level carbon transparency, strengthen competitiveness in government procurement that emphasizes ESG performance, and improve overall supply-chain resilience.

Green research: From molecule to patient with lower environmental impact

In Green Research, WuXi Biologics starts with its guiding principle ‘For Patients. For Planet’. The company leverages its integrated end-to-end CRDMO platform and innovative technologies to shorten the journey from molecule to patient.

Discovery platforms such as WuXiBody™ accelerate the development of antibodies and complex molecules, improve developability and stability, and enable innovative therapies to reach patients faster, at greater scale and with higher quality.

By simplifying bispecific antibody development and shortening research and development timelines by 6–18 months, WuXiBody™ improves R&D efficiency while reducing the natural resources and energy required to maintain research environments.

Green development: High-yield, lower-carbon biologics development

In Green Development, WuXi Biologics uses advanced platforms including WuXia™, WuXiUP™ and WuXiUI™ to improve productivity, reduce resource use and provide more efficient and flexible process pathways for innovative biologics.

The WuXia™ TrueSite cell line development platform further improves development efficiency and quality through technological innovation. It achieves monoclonal antibody titers of 8–12 g/L, supporting high-yield commercial manufacturing requirements, and shortens the timeline from DNA to IND filing readiness to approximately six months.

The WuXiUI™ ultra-intensified fed-batch platform boosts productivity by 3 to 8 times and reduces lifecycle environmental impacts by up to 60% compared with traditional fed-batch processes. This makes development lower-carbon, more efficient and more sustainable, while improving capacity, quality consistency and operational agility.

Green manufacturing: Scaling single-use technology and lifecycle assessment

In Green Manufacturing, WuXi Biologics leverages single-use technology (SUT) and process innovation to scale green manufacturing. Compared with traditional stainless-steel processes, SUT can save up to 70% of water, reduce resource use by approximately 33%, and lower negative climate-change impacts by approximately 40%. End-of-life treatment accounts for only 1%–3% of its lifecycle environmental impact and is therefore considered negligible.

WuXi Biologics remains committed to responsible waste management through zero waste to landfill, waste-to-energy utilization, continued reduction of SUT waste, and exploration of more environmentally friendly SUT recycling solutions.

Combining WuXiUI™ with SUT can reduce the product carbon footprint per gram of protein by up to 80%, providing clients with manufacturing solutions that deliver both environmental and operational benefits.

The company also uses lifecycle assessment (LCA) modeling and calculation capabilities to support cradle-to-gate product carbon-footprint measurements and enable product-level carbon transparency. Clearer, traceable carbon data helps clients make better low-carbon decisions, manage Scope 3 emissions and advance value-chain decarbonization.

Green operations: Embedding sustainability across global sites

In Green Operations, WuXi Biologics embeds sustainability across its global operations and uses lean management and digital tools to improve resource and energy efficiency. These initiatives deliver further reductions in carbon emissions, water use and waste.

The Green CRDMO solution was selected as a United Nations Global Compact ‘20 Cases for 20 Years’ corporate sustainability case. The WuXi Biologics Green CRDMO White Paper systematically shares practices across green research, development, manufacturing and operations. It outlines 242 energy-saving cases covering 12 major energy systems and five key energy-saving scenarios across 25 categories of energy-saving technologies, supporting the replication of green operational practices across global sites and the wider industry value chain.

Climate action and SBTi-validated net-zero targets

Climate action remains a central pillar of the Green CRDMO strategy at WuXi Biologics. The company has obtained SBTi validation for its near-term, long-term and net-zero targets, and has committed to achieving net-zero emissions across its value chain by 2050.

To support these ambitions, WuXi Biologics continues to advance energy efficiency initiatives, renewable energy adoption, green operations and supply-chain collaboration. BioPharma APAC specifically highlighted the company’s SBTi-approved targets and commitment to sustainable transformation within the biopharmaceutical industry.

Global ESG recognition for sustainable biopharma leadership

WuXi Biologics has received sustained international recognition for its sustainability performance. The company has achieved the highest MSCI AAA ESG rating and the EcoVadis Platinum Medal, placing it in the global top 1%. It has been included in the Dow Jones Best-in-Class World Index and Dow Jones Best-in-Class Emerging Markets Index.

The company has also received CDP ‘A List’ recognition for Climate Change, Water Security and Supplier Engagement Assessment. It holds the highest ‘Negligible Risk’ rating from Morningstar Sustainalytics and is recognized as an ESG Industry and Regional ESG Leader.

WuXi Biologics is also included in the FTSE4Good Index Series, has been awarded ISS ESG Prime status, and is part of the Hang Seng Corporate Sustainability Benchmark Index.

These recognitions underscore the company’s progress across environmental, social and governance areas, as well as global stakeholder recognition of its sustainability strategy and performance.

Advancing green manufacturing for resilience and competitiveness

Green manufacturing is not only an important sustainability commitment, but also a key pathway to enhancing competitiveness, productivity and operational resilience in the biopharmaceutical sector.

WuXi Biologics will continue to advance green technology innovation and create shared sustainable value for global partners through its end-to-end Green CRDMO solution. The company aims to work with stakeholders across the value chain toward a greener and healthier future.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>